Biomarkers for Human Heart Failure

The purpose of this study is to establish the various ranges of proteins that can be assayed in the plasma and urine from hospitalized patients with all classes of heart failure and/or STEMI (ST-segment elevation myocardial infarction)/NSTEMI (Non-ST-segment elevation myocardial infarction), as well as history reviews.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

CHF

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Foundation

Rochester, Minnesota, 55905, United States

About this study

Schematic Design of the Study: Single blood draw, one random urine and 24-hr urine collection from hospitalized patients with chronic/acute heart failure and/or STEMI-NSTEMI. If there should be a subsequent hospitalization,another collection of a 45 ml blood sample, random urine and one 24-hour urine collection may be completed if indicated at initial hospitalization.

Aims:

The purpose of this study is to attempt to establish the various ranges of proteins that can be assayed from the plasma and urine of patients with all classes of heart failure and MI (myocardial infarction). Follow-up hospitalizations may result in another 45 ml blood draw, random urine and 24-hr. urine collection to evaluate the outcome of the heart failure treatment used with the previous hospitalization, if indicated in consent. A history review will be necessary as well.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of Acute decompensated heart failure

Exclusion criteria

Hemoglobin less than 10, active cancer, or amyloidosis Patient with dialysis

Treatment and study plan

sample analysis

Other

blood, Random urine sample and 24-hour urine samples

Primary outcomes

uAGT levels in high-risk chronic HF patients

Time frame: 10 years

This study will provide new knowledge of the pathology and outcomes predicted by the use of uAGT in symptomatic chronic HF patients at high risk for future hospitalization and death.
Natriuretic peptide levels in ADHF patients

Time frame: 20 years

new knowledge of pathology and outcomes in ADHF patients

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Acronym: Biomarkers

Important dates

Study start: 2009
Primary completion: 2024
Study completion: 2024
First posted: Apr 5, 2019
Registry last updated: May 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed